TUKYSA

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, Finland, France, Ireland, Israel, Lithuania, Poland, Romania, Spain.

Active ingredients

The drug TUKYSA contains one active pharmaceutical ingredient (API):

1	Tucatinib UNII 234248D0HH - TUCATINIB
	Tucatinib is a tyrosine kinase inhibitor of HER2. It is used in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
	Read more about Tucatinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TUKYSA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
TUKYSA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EH03		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
Discover more medicines within L01EH03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02499827, 02499835
EE	Ravimiamet	1842544, 1842555, 1862647
ES	Centro de información online de medicamentos de la AEMPS	1201526001, 1201526002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	037635, 408097
FR	Base de données publique des médicaments	61156829, 69401038
IL	מִשְׂרַד הַבְּרִיאוּת	9038, 9039
LT	Valstybinė vaistų kontrolės tarnyba	1092085, 1092086
PL	Rejestru Produktów Leczniczych	100448401, 100448418
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69027001, W69028001
US	FDA, National Drug Code	51144-001, 51144-002